Skip to main content

Generic Forteo Availability

Last updated on Nov 8, 2022.

Forteo is a brand name of teriparatide, approved by the FDA in the following formulation(s):

FORTEO (teriparatide - solution;subcutaneous)

  • Manufacturer: LILLY
    Approval date: November 26, 2002
    Strength(s): 0.75MG/3ML (0.25MG/ML) (discontinued)
  • Manufacturer: LILLY
    Approval date: June 25, 2008
    Strength(s): 0.6MG/2.4ML (0.25MG/ML) [RLD]

Has a generic version of Forteo been approved?

A follow-on teriparatide product (Bonsity) has been approved under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug.

teriparatide -solution;subcutaneous

  • Manufacturer: ALVOGEN INC.
    Approval date: October 4, 2019
    Strength: 0.62MG/2.48ML (0.25MG/ML)

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Forteo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
    Patent 7,517,334
    Issued: April 14, 2009
    Inventor(s): Jacobs; Alexander Thomas & Judson; Jared Alden & Row; Gordon Davidson
    Assignee(s): Eli Lilly and Company

    A medication dispensing apparatus with a spring-driven locking feature includes a drive member movable in a distal direction within a housing, and a fluid container with a piston that is advanceable by the drive member (60) when such drive member is moved distally by a driving means. The apparatus includes a latching element (180) having a skid (190) that is slidable along a surface of the drive member as the drive member passes distally during advancement. The drive member is arranged with the skid so as to maintain a latching lip of the latching element against a spring force in a first position free of the driving means during dose preparing and injecting prior to a final dose administration. The skid-engaging surface shifts distally of the skid such that the skid passes beyond a proximal end of that surface upon administration of a final dose, whereby the latching lip is urged by the spring force from the first position to a second position to physically lock the driving means to prevent further dose preparing and injecting.

    Patent expiration dates:

    • March 25, 2025
      Drug product


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.